MedTrace Logo

Pulmonary Arterial Hypertension in Patients With Direct-Acting Antiviral Medications for Hepatitis C Virus Infection

NCT04094272 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 49

Last updated 2019-09-23

No results posted yet for this study

Summary

The purpose of this study is the evaluation of PAH in patients, who are treated with DAA medication for HCV infection.

Conditions

  • Pulmonary Artery Hypertension
  • Chronic Hepatitis c

Interventions

DIAGNOSTIC_TEST

transthoracic doppler-echocardiography (TTE)

Transthoracic doppler-echocardiography (TTE) in patients with a new diagnosis of HCV before and after treatment with DAA medication.

Sponsors & Collaborators

  • Kantonsspital Olten

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2019-05-01
Completion
2019-06-01

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04094272 on ClinicalTrials.gov